1.
Menotti M, Ambrogio C, Cheong T-C, et al. Wiskott-Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma. Nat Med. 2019;25(1):130-140. doi:10.1038/s41591-018-0262-9.
1.
Luo T, Masson K, Jaffe JD, et al. STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability. Proc Natl Acad Sci U S A. 2012;109(8):2860-5. doi:10.1073/pnas.1120589109.
1.
Ferguson BS, Harrison BC, Jeong MY, et al. Signal-dependent repression of DUSP5 by class I HDACs controls nuclear ERK activity and cardiomyocyte hypertrophy. Proc Natl Acad Sci U S A. 2013;110(24):9806-11. doi:10.1073/pnas.1301509110.
1.
Dardaei L, Wang HQ, Singh M, et al. SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. Nat Med. 2018;24(4):512-517. doi:10.1038/nm.4497.
1.
Antipova AA, Stockwell BR, Golub TR. Gene expression-based screening for inhibitors of PDGFR signaling. Genome Biol. 2008;9(3):R47. doi:10.1186/gb-2008-9-3-r47.
1.
Lin WM, Baker AC, Beroukhim R, et al. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 2008;68(3):664-73. doi:10.1158/0008-5472.CAN-07-2615.
1.
Boehm JS, Zhao JJ, Yao J, et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell. 2007;129(6):1065-79. doi:10.1016/j.cell.2007.03.052.
1.
Cheung HW, Du J, Boehm JS, et al. Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov. 2011;1(7):608-25. doi:10.1158/2159-8290.CD-11-0046.
1.
Huillard E, Hashizume R, Phillips JJ, et al. Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. Proc Natl Acad Sci U S A. 2012;109(22):8710-5. doi:10.1073/pnas.1117255109.
1.
Randlett O, Wee CL, Naumann EA, et al. Whole-brain activity mapping onto a zebrafish brain atlas. Nat Methods. 2015;12(11):1039-46. doi:10.1038/nmeth.3581.